Clinical Trial News and Research

RSS

FDA issues complete response letter to Bristol-Myers Squibb and AstraZeneca's dapagliflozin

Bristol-Myers Squibb Company and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for investigational compound dapagliflozin for the treatment of type 2 diabetes in adults.

19 Jan 2012

Experimental drug helps patients with advanced colon cancer

According to results from a new clinical trial, an experimental cancer drug regorafenib appears to extend survival slightly in patients with metastatic colorectal cancer. Regorafenib is a so-called multikinase inhibitor, which targets several of the ways cancer develops and grows, researchers said.

19 Jan 2012

Study demonstrates possibility of curing hepatitis C without use of interferon

Bristol-Myers Squibb Company today announced the full results, published in the New England Journal of Medicine, from a Phase II clinical trial in patients with hepatitis C virus (HCV) genotype 1 who had not responded to prior therapy with PEG-interferon alfa and ribavirin ('null responders').

19 Jan 2012

Henry Ford to conduct Apnex HGNS System clinical trial in OSA

A clinical trial is underway at Henry Ford Hospital to evaluate the safety and effectiveness of the Apnex Hypoglossal Nerve Stimulation System to treat obstructive sleep apnea.

19 Jan 2012

New combo drug helps suppress hepatitis C genotype 1 infection

A new combination of investigational drugs successfully suppressed hepatitis C genotype 1 infection in a high percent of patients who had not responded to previous treatment in a study led by a University of Michigan hepatologist.

19 Jan 2012

Study identifies mechanism that AML cells use to evade chemotherapy

A study published this week in the journal Leukemia identifies a mechanism that acute myeloid leukemia (AML) cells use to evade chemotherapy - and details how to close this escape route.

19 Jan 2012

Rexahn receives approval to initiate RX-3117 Phase I trial in solid tumors

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing oncology and CNS therapeutics, today announced that it has secured Hungarian Regulatory Authority and Ethics Committee approval for Rexahn's initial Clinical Trial Application.

19 Jan 2012

Pfizer and Medivation drop further testing of failed Alzheimer’s drug

A phase III clinical trial of an investigational Alzheimer's disease drug dimebon failed to show encouraging results dooming its future according to its commercial sponsors.

18 Jan 2012

National Commission accredits ABCC Diplomate of Comprehensive Care program

The American Board of Comprehensive Care (ABCC), based at the Columbia University School of Nursing (CUSON), is an independent organization founded in 2007 for the purpose of certifying nurse practitioner graduates of Doctor of Nursing Practice (DNP) programs who have met defined and accepted standards for comprehensive care.

18 Jan 2012

Minimally invasive renal denervation performed for the first time in Canada

Doctors at the Peter Munk Cardiac Centre today performed a minimally invasive surgical procedure to treat high blood pressure, called renal denervation, for the first time in Canada.

18 Jan 2012

Memory retraining using mSMT increases cerebral activation in MS patients

Neuroscientists at Kessler Foundation have documented increased cerebral activation in patients with multiple sclerosis (MS) following memory retraining using the modified Story Memory Technique (mSMT).

18 Jan 2012

Peter Munk Cardiac Centre doctors perform renal denervation in first Canadian patient

Doctors at the Peter Munk Cardiac Centre today performed a minimally invasive surgical procedure to treat high blood pressure, called renal denervation, for the first time in Canada. The procedure can significantly reduce high blood pressure in patients who cannot effectively treat their hypertension through drugs. These patients, numbering approximately 250,000 Canadians, have to endure an especially high risk of heart attacks and stroke, which continues to kill thousands of Canadians every year.

18 Jan 2012

Regorafenib lengthens lives of patients with metastatic colorectal cancer

An investigational drug called regorafenib slowed the progression of tumors and lengthened the lives of patients with metastatic colorectal cancer, an international phase III clinical trial found. The findings were presented today at the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology in San Francisco by Mayo Clinic oncologist Axel Grothey, M.D., principal investigator of the trial in the United States.

17 Jan 2012

Medtronic announces CE mark and launch of Endurant II AAA Stent Graft System

Medtronic Inc. today announced the CE mark and international launch of the Endurant II AAA Stent Graft System, which meaningfully expands the options physicians outside the United States have to treat patients with abdominal aortic aneurysms through a minimally invasive technique called endovascular aortic repair.

From Medtronic 17 Jan 2012

BJALCF receives $1 million in grants for 2012 Lung Cancer Research

Just two months shy of marking its 7-year anniversary, BJALCF announced today that it has awarded over $1 million in grants for 2012 Lung Cancer Research. BJALCF has made a promise to the Lung Cancer Community to fund only immediate results-oriented projects or programs promising to catalyze progress through early detection, genetic testing, drug discovery and patient-focused outcomes.

17 Jan 2012

Matted lymph nodes may predict throat cancer metastasis

Researchers at the University of Michigan Health System have found a new indicator that may predict which patients with a common type of throat cancer are most likely have the cancer spread to other parts of their bodies.

17 Jan 2012

MD Anderson Orlando receives donation to fight against pancreatic cancer

MD Anderson Cancer Center Orlando has received a generous donation to help in the fight against pancreatic cancer. A $75,000 grant, funded by the Shirley E. Noland Foundation, will support the Pancreatic Cancer Translational Research Project at MD Anderson - Orlando.

17 Jan 2012

Positive outcomes from Boston Scientific's Epic Stent trial on iliac artery disease

Boston Scientific Corporation reports nine-month clinical endpoint data from its ORION trial, demonstrating excellent outcomes for the Company's Epic Self-Expanding Nitinol Stent System in patients with iliac artery disease, a form of peripheral artery disease associated with severe leg pain caused by insufficient blood flow.

16 Jan 2012

AxoGen reports results from Avance Nerve Graft clinical study on PNI

AxoGen, Inc., an emerging regenerative medicine company focused on the commercialization of proprietary products and technologies for peripheral nerve reconstruction and regeneration, today reported the publication of peer-reviewed clinical research conducted at twelve leading US surgical sites and led by the Buncke Clinic in San Francisco.

16 Jan 2012

MYTHOS clinical trial demonstrates superiority of RenalGuard in reducing CIN

PLC Systems Inc., a company focused on innovative medical device technologies, today announced that final results from the MYTHOS investigator-sponsored clinical trial of RenalGuard in Italy have been published in the January 2012 issue of JACC – Cardiovascular Interventions, a peer-reviewed journal of the American College of Cardiology.

13 Jan 2012